目次

Table of Content

1. Introduction to Next Generation Multispecific Antibodies

2. Multispecific Antibody Current Clinical Development and Future Commercialization Outlook
2.1 Current Market Overview
2.2 Future Commercialization Opportunity

3. Multispecific Antibody Proprietary Technologies by Company

4. Multispecific Antibody Clinical Development and Market Trends by Region
4.1 US
4.2 EU
4.3 China
4.4 UK
4.5 Japan
4.6 Australia
4.7 South Korea
4.8 Canada

5. Multispecific Antibody Clinical Trends by Indication
5.1 Cancer
5.2 Hematological Disorders
5.3 Microbial Infections
5.4 Autoimmune and Inflammatory Disorders
5.5 Ocular Diseases

6. Approved Multispecific Antibodies - Clinical Overview, Pricing and Dosage Insight
6.1 Overview
6.2 Clinical Overview, Pricing and Dosage Insight

7. Approved Multispecific Antibodies - Sales Insight ( 2020 - H1’2024)

8. Global Multispecific Antibodies Clinical Trials Overview (2024 - 2029)
8.1 By Phase
8.2 By Country/Region
8.3 By Company
8.4 By Indication
8.5 By Priority Status
8.6 Patient Segment

9. Global Bispecific Antibodies Clinical Trials By Company, Indication and Phase
9.1 Research
9.2 Preclinical
9.3 Phase-I
9.4 Phase-I/II
9.5 Phase-II
9.6 Phase-II/III
9.7 Phase-III
9.8 Preregistration

10. Marketed Bispecific Antibodies Clinical Insight By Company, Country and Indication

11. Global Trispecific Antibodies Clinical Trials Insight By Company, Country, Indication and Phase
11.1 Research
11.2 Preclinical
11.3 Phase I
11.4 Phase I/II

12. Tetraspecific Antibodies Clinical Trials Insight By Company, Country, Indication and Phase
12.1 Preclinical
12.2 Phase I
12.3 Phase I/II
12.4 Phase II

13. Competitive Landscape
13.1 AbbVie
13.2 ABL Bio
13.3 Abzyme Therapeutics
13.4 Affimed Therapeutics
13.5 Akeso Biopharma
13.6 Alligator Bioscience
13.7 Amgen
13.8 Antibody Therapeutics
13.9 APITBIO
13.10 Astellas Pharma
13.11 AstraZeneca
13.12 Aptevo Therapeutics
13.13 BioAtla
13.14 Biocytogen Pharmaceuticals
13.15 Biosion
13.16 EpimAb Biotherapeutics
13.17 FutureGen Biopharmaceutical
13.18 Genentech
13.19 Genmab
13.20 Genor Biopharma
13.21 Gensun Biopharma
13.22 Harbour BioMed
13.23 Harpoon Therapeutics
13.24 IGM Biosciences
13.25 I-MAB Biopharma
13.26 ImmuneOnco Biopharma
13.27 ImmunoPrecise Antibodies
13.28 Innate Pharma
13.29 Innovent Biologics
13.30 Invenra
13.31 Kenjockety Biotechnology
13.32 LaNova Medicines Limited
13.33 Light Chain Bioscience
13.34 Linton Pharm
13.35 Lyvgen Biopharma
13.36 MacroGenics
13.37 Merus
13.38 ModeX Therapeutics (OPKO Health)
13.39 Molecular Partners
13.40 NovaRock Biotherapeutics
13.41 Numab
13.42 OPKO Health
13.43 Pfizer
13.44 Regeneron Pharmaceuticals
13.45 Revitope
13.46 Roche
13.47 Ruijin Hospital
13.48 Sanofi
13.49 Sichuan Baili Pharmaceutical
13.50 SystImmune
13.51 Virtuoso Therapeutics
13.52 Xencor
13.53 Y-Biologics
13.54 Zhejiang Shimai Pharmaceutical
13.55 Zymeworks

List of Figures & Tables
List of Figures & Table
Figure 2-1: Global -Multispecific Antibodies Sales (US$ Million), 2020-2024
Figure 2-2: Global - Market Sales by Multispecific Antibodies (US$ Million), 2024
Figure 2-3: Global -Market Sales by Multispecific Antibodies (%), 2024
Figure 2-4: Global - Quarterly Sales By Multispecific Antibodies (US$ Million), 2024
Figure 2-5: Global - Quarterly Sales By Multispecific Antibodies (%), 2024
Figure 2-6: US - Quarterly Sales By Multispecific Antibodies (US$ Million), 2024
Figure 2-7: ROW - Quarterly Sales By Multispecific Antibodies (US$ Million), 2024
Figure 2-8: Global - Multispecific Antibodies Market Opportunity Assessment (US$ Billion), 2024 - 2029
Figure 3-1: Grabody I Platform - Mechanism of Action
Figure 3-2: Grabody I Platform - Mechanism of Action
Figure 3-3: Abz2 Bispecific Platform
Figure 3-4: Abz2 Bispecifics - Benefits
Figure 3-5: Neo-X-Prime Bispecific Mechanism
Figure 3-6: BiTE - Structure
Figure 3-7: BiTE Molecule
Figure 3-8: ADAPTIR Bispecific Structure
Figure 3-9: ADAPTIR-FLEX
Figure 3-10: BioAtla CABs - Features
Figure 3-11: BioAtla CABs - Benefits
Figure 3-12: FIT-Ig - Proprietary Bispecific Platform
Figure 3-13: 3-Step DuoBody Production Process
Figure 3-14: DuoHexaBody Molecules - Schematic
Figure 3-15: BEAT Platform - Multispecific Antibodies
Figure 3-16: IMBiologic Bispecific Antibodies - Strategy
Figure 3-17: IMBiologic Bispecific Antibodies - Mechanism of Action
Figure 3-18: ANKETandreg; Platform - Innate Pharma
Figure 3-19: B-Body Bispecific Antibody - Structre
Figure 3-20: iTAb - Patented Structure
Figure 3-21: iTAb - Mechanism of Action
Figure 3-22: xLinkBsAb - Structure
Figure 3-23: Multiclonics - Distinctive Characteristics
Figure 3-24: Biclonics - Format
Figure 3-25: Merus - Triclonics Platform
Figure 3-26: STEALTH - ModeX Therapeutics
Figure 3-27: MSTAR - ModeX Therapeutics
Figure 3-28: MSTAR - Features
Figure 3-29: DARPin Platform - Molecular Partners
Figure 3-30: Novel HBICE
Figure 3-31: HBICE - Mechanism of Action
Figure 3-32: HBICE - Mechanism of Action
Figure 3-33: Numab Therapeutics - Technology
Figure 3-34: Phanes Therapeutics - PACbody Platform
Figure 3-35: Phanes Therapeutics - SPECpair Platform
Figure 3-36: Phanes Therapeutics - ATACCbody
Figure 3-37: Purple Biotech - Tribody Antibody Platform
Figure 3-38: PrecisionGATE Bispecific Antibody - Structure
Figure 3-39: Sanyou Super Trillion Common Light Chain Antibody Discovery Platform
Figure 3-40: GNC Antibodies - Sichuan Baili Pharmaceutical/SystImmune
Figure 3-41: Synimmune - Proprietary Bispecific Antibody Format
Figure 3-42: ALiCE - Characteristics
Figure 3-43: ALiCE - Schematic Diagram and Mechanism of Action
Figure 3-44: BiClone format
Figure 3-45: Zyngenia Technology Approach
Figure 4-1: US - Approved Bispecific Antibodies
Figure 4-2: Chugai Files New Drug Application in Japan for Mosunetuzumab, anti-CD20xCD3 bispecific antibody
Figure 4-3: Chugai Pharmaceutical - Multispecific Antibody Clinical Pipeline
Figure 4-4: SAIL66 Phase I Study (NCT05735366) - Initiation and Completion Year
Figure 4-5: Japan Next Generation Multispecific Antibody Market - Insight
Figure 4-6: Hoffmann La Roche AG Patent (JP2018502835A) - Grant and Expiration Year
Figure 4-7: DR-0201 Phase I Study (NCT06392477) - Initiation and Completion Year
Figure 4-8: Australia - Universities and Research Centers Conducting Next Generation Multispecific Antibody Clinical Trials
Figure 4-9: ABL Bio - Bispecific Antibody Pipeline
Figure 4-10: Multispecific Antibody Combinations
Figure 4-11: CTX-009 (ABL001) Phase I/II Study (NCT04492033) - Initiation and Completion Year
Figure 4-12: Elranatamab Phase II Study (NCT06421675) - Initiation and Completion Year
Figure 4-13: Canada Next Generation Multispecific Antibodies - Key Players
Figure 5-1: Odronextamab (ELM-1) Phase I (NCT02290951) Study - Initiation and Completion Year
Figure 5-2: Odronextamab (ELM-1) Phase II (NCT03888105) Study - Initiation and Completion Year
Figure 5-3: Linvoseltamab (LINKER-MM1) Phase I/II (NCT03761108) Study - Initiation and Completion Year
Figure 5-4: PIT565 Phase I (NCT05397496) Study - Initiation and Completion Year
Figure 5-5: JNJ-79635322 Phase I (NCT05652335) Study - Initiation and Completion Year
Figure 5-6: GNC-038 Phase I/II (NCT05192486) Study - Initiation and Completion Year
Figure 5-7: GNC-038 Phase I/II (NCT05485753) Study - Initiation and Completion Year
Figure 5-8: IPH6501 Phase I/II (NCT06088654) Study - Initiation and Completion Year
Figure 5-9: NM32-2668 Phase I (NCT06299163) Study - Initiation and Completion Year
Figure 5-10: GB263T Phase I/II (NCT05332574) Study - Initiation and Completion Year
Figure 5-11: GNC-039 Phase I (NCT04794972) Study - Initiation and Completion Year
Figure 5-12: Emicizumab Phase II (NCT05345197) Study - Initiation and Completion Year
Figure 5-13: Emicizumab Phase II/III (NCT06155955) Study - Initiation and Completion Year
Figure 5-14: Emicizumab (BCDI-XII) Phase I (NCT05500807) Study - Initiation and Completion Year
Figure 5-15: HMB-001 Phase I/II (NCT06211634) Study - Initiation and Completion Year
Figure 5-16: YBSW015 Early Phase I (NCT05369754) Study - Initiation and Completion Year
Figure 5-17: GR1801 Phase III (NCT05846568) Study - Initiation and Completion Year
Figure 5-18: Imvotamab (IGM-2323-101) Phase I (NCT06041568) Study - Initiation and Completion Year
Figure 5-19: Imvotamab (IGM-2323-102) Phase I (NCT06087406) Study - Initiation and Completion Year
Figure 5-20: PRV-3279 (PREVAIL-2) Phase II (NCT05087628) Study - Initiation and Completion Year
Figure 5-21: DONQ52 (DQB101US) Phase I (NCT05425446) Study - Initiation and Completion Year
Figure 5-22: Mosunetuzumab (GA43191) Phase I (NCT05155345) Study - Initiation and Completion Year
Figure 5-23: Faricimab (MAGIC) Phase II (NCT05681884) Study - Initiation and Completion Year
Figure 5-24: Restoret (EYE103) - Tetravalent, Tri-Specific Antibody Binding Sites
Figure 5-25: EYE103 (AMARONE) Phase I/II Study (NCT05919693) - Initiation and Completion Year
Figure 6-1: Blincyto - Approval Year by Region
Figure 6-2: Blincyto - Patent Filing and Expiration Year
Figure 6-3: Blincyto - Treatment Regimen Cycles (Weeks)
Figure 6-4: Blincyto - Duration of Treatment Phase and Resting Phase in Induction and Consolidation Cycles for Treatment of MRD-Positive B-cell precursor (Days)
Figure 6-5: Blincyto - Cost of Single Cycle and Treatment Course for the Treatment of MRD-positive B-cell Precursor ALL
Figure 6-6: Blincyto - Recommended Number of Induction and Consolidation Treatment Cycle for Relapsed B-Cell Precursor ALL
Figure 6-7: Blincyto - Duration of Single Induction, Consolidation, Continued Cycle and Full Treatment for Relapsed B-Cell Precursor ALL (Weeks)
Figure 6-8: Blincyto - Cost of Single Cycle and Treatment Course for Treatment for Relapsed B-Cell Precursor ALL
Figure 6-9: Hemlibra - Approval Years by Region
Figure 6-10: Hemlibra - Cost per Unit and Supply of 30 mg/mL Subcutaneous Injection of Different Volumes (US$), July’2024
Figure 6-11: Hemlibra - Cost per Unit and Supply of 150 mg/mL Subcutaneous Injection of Different Volumes (US$), July’2024
Figure 6-12: Hemlibra - Recommended Loading and Maintenance Dose for Treatment of Hemophilia (mg/kg/Week)
Figure 6-13: Rybrevant - Price per Unit and Supply of Intravenous Solution (US$), July’2024
Figure 6-14: Rybrevant - Recommended Dose per Cycle by Body Weight (mg)
Figure 6-15: Rybrevant - Dose Reduction in Patients with Weight less than 80 kg (mg)
Figure 6-16: Rybrevant - Dose Reduction in Patients with Weight more than 80 Kg (mg)
Figure 6-17: Vabysmo - First Approval Year by Region
Figure 6-18: Vabysmo - Price per Unit and Supply of Intravitreal Solution (US$), July’2024
Figure 6-19: Lunsumio - Approval Years by Region
Figure 6-20: US - Price per Unit and Supply of Lunsumio Intravenous Solution (US$), July’2024
Figure 6-21: EU - Price per Unit and Supply of Lunsumio Intravenous Solution (US$), July’2024
Figure 6-22: Tecvayli - Approval Years by Region
Figure 6-23: Tecvayli - Patent Acceptance and Expiration Years
Figure 6-24: US - Cost per Unit and Supply of Tecvayli Subcutaneous Solution (US$), July’2024
Figure 6-25: EU - Cost per Unit and Supply of Tecvayli Subcutaneous Solution (US$), July’2024
Figure 6-26: Columvi - Approval Year by Region
Figure 6-27: US - Price per Unit and Supply of Columvi Intravenous Solution (US$), July’2024
Figure 6-28: EU - Price per Unit and Supply of Columvi Intravenous Solution (US$), July’2024
Figure 6-29: Epkinly - Approval Year by Region
Figure 6-30: US - Cost per Unit and Supply of Epkinly Subcutaneous Solution (US$), July’2024
Figure 6-31: EU - Cost per Unit and Supply of Epkinly Subcutaneous Solution (US$), July’2024
Figure 6-32: Talvey - Approval Year by Region
Figure 6-33: Talquetamab - FDA and EMA Designation Year
Figure 6-34: Talvey - Patent Acceptance and Expiration Year
Figure 6-35: US - Price per Unit and Supply of Talvey Intravenous Solution (US$), July’2024
Figure 6-36: EU - Price per Unit and Supply of Talvey Intravenous Solution (US$), February’2024
Figure 6-37: Elrexfio - Approval Years by Region
Figure 6-38: Elranatamab - FDA and EMA Designation Year
Figure 6-39: US - Price per Unit and Supply of Elrexfio Subcutaneous Solution (US$), July’2024
Figure 7-1: Global - Annual Blincyto Sales (US$ Million), 2020-2024
Figure 7-2: Global - Quarterly Blincyto Sales (US$ Million), 2024
Figure 7-3: Blincyto - US v/s ROW Sales (US$ Million), H1’2024
Figure 7-4: Global - Blincyto Sales by Region (%), Q1’2024
Figure 7-5: US - Quarterly Blincyto Sales (US$ Million), 2024
Figure 7-6: ROW - Quarterly Blincyto Sales (US$ Million), H1’2024
Figure 7-7: Global - Quarterly Blincyto Sales (US$ Million), 2023
Figure 7-8: US - Quarterly Blincyto Sales (US$ Million), 2023
Figure 7-9: ROW - Quarterly Blincyto Sales (US$ Million), 2023
Figure 7-10: US - Annual Blincyto Sales (US$ Million), 2020-2024
Figure 7-11: ROW - Annual Blincyto Sales (US$ Million), 2019-2023
Figure 7-12: Global - Annual Hemlibra Sales (US$ Million), 2020-2024
Figure 7-13: Regional - US v/s ROW Sales (US$ Million), H1’2024
Figure 7-14: Global - Hemlibra Sales by Region (US$ Million), H1’2024
Figure 7-15: Global - Hemlibra Sales by Region (%), H1’2024
Figure 7-16: US - Annual Hemlibra Sales (US$ Million), 2020-2024
Figure 7-17: Europe - Annual Hemlibra Sales (US$ Million), 2020-2024
Figure 7-18: Japan - Annual Hemlibra Sales (US$ Million), 2020-2024
Figure 7-19: ROW - Hemlibra Sales (US$ Million), 2020-2024
Figure 7-20: Global - Hemlibra Annual Sales by Region (US$ Million), 2023
Figure 7-21: Global - Hemlibra Sales by Region (%), 2023
Figure 7-22: Global - Quarterly Hemlibra Sales (US$ Million), 2023
Figure 7-23: US - Quarterly Hemlibra Sales (US$ Million), 2023
Figure 7-24: Europe - Quarterly Hemlibra Sales (US$ Million), 2023
Figure 7-25: Japan - Quarterly Hemlibra Sales (US$ Million), 2023
Figure 7-26: ROW - Quarterly Hemlibra Sales (US$ Million), 2023
Figure 7-27: Global - Annual Vabysmo Sales (US$ Million), 2022-2024
Figure 7-28: Global - Vabysmo US v/s ROW Sales (US$ Million), H1’2024
Figure 7-29: Global - Vabysmo Sales by Region (US$ Million), H1’2024
Figure 7-30: Global - Vabysmo Annual Sales by Region (%), H1’2024
Figure 7-31: Global - Vabysmo US v/s ROW Sales (US$ Million), 2023
Figure 7-32: Global - Vabysmo Annual Sales by Region (US$ Million), 2023
Figure 7-33: Global - Vabysmo Annual Sales by Region (%), 2023
Figure 7-34: US - Vabysmo Sales (US$ Million), 2022-2024
Figure 7-35: Europe - Vabysmo Sales (US$ Million), 2022-2024
Figure 7-36: Japan - Vabysmo Sales (US$ Million), 2022-2024
Figure 7-37: ROW - Vabysmo Sales (US$ Million), 2022-2024
Figure 7-38: Global - Quarterly Vabysmo Sales (US$ Million), 2023
Figure 7-39: US - Quarterly Vabysmo Sales (US$ Million), 2023
Figure 7-40: Europe - Quarterly Vabysmo Sales (US$ Million), 2023
Figure 7-41: Japan - Quarterly Vabysmo Sales (US$ Million), 2023
Figure 7-42: ROW - Quarterly Vabysmo Sales (US$ Million), 2023
Figure 7-43: Global - Annual Lunsumio Sales (US$ Million), 2022-2024
Figure 7-44: US - Annual Lunsumio Sales (US$ Million), 2022-2024
Figure 7-45: Europe - Annual Lunsumio Sales (US$ Million), 2022-2024
Figure 7-46: Global - Lunsumio Sales by Region (US$ Million), H1’2024
Figure 7-47: Global - Lunsumio Sales by Region (%), H1’2024
Figure 7-48: Global - Lunsumio Annual Sales by Region (US$ Million), 2023
Figure 7-49: Global - Lunsumio Annual Sales by Region (%), 2023
Figure 7-50:- Global -Lunsumio Sales (US$ Million), Q1 - Q4’2023
Figure 7-51: US - Quarterly Lunsumio Sales (US$ Million), 2023
Figure 7-52: Europe - Quarterly Lunsumio Sales (US$ Million), 2023
Figure 7-53: Global - Annual Tecvayli Sales (US$ Million), 2024
Figure 7-54: Regional - US v/s ROW Sales (US$ Million), H1’2024
Figure 7-55: Global - Tecvayli Sales by Region (%), H1’2024
Figure 7-56: Global - Quarterly Tecvayli Sales (US$ Million), 2024
Figure 7-57: US - Quarterly Tecvayli Sales (US$ Million), 2024
Figure 7-58: ROW - Quarterly Tecvayli Sales (US$ Million), 2024
Figure 7-59: Global - Quarterly Tecvayli Sales (US$ Million), 2023
Figure 7-60: US - Quarterly Tecvayli Sales (US$ Million), 2023
Figure 7-61: ROW - Quarterly Tecvayli Sales (US$ Million), 2023
Figure 7-62: Global - Annual Columvi Sales (US$ Million), 2022-2024
Figure 7-63: Global - Columvi Sales by Region (US$ Million), H1’2024
Figure 7-64: Global - Columvi Sales by Region (%), H1’2024
Figure 7-65: Global - Columvi Sales by Region (US$ Million), 2023
Figure 7-66: Global - Columvi Sales by Region (%), 2023
Figure 7-67: Global - Quarterly Columvi Sales (US$ Million), 2023
Figure 7-68: US - Quarterly Columvi Sales (US$ Million), 2023
Figure 7-69: Europe - Quarterly Columvi Sales (US$ Million), 2023
Figure 7-70: Global - Annual Epkinly Sales (US$ Million), 2023-2024
Figure 7-71: Global - Quarterly Epkinly Sales (US$ Million), 2024
Figure 7-72: Global - Quarterly Epkinly Sales (US$ Million), 2023
Figure 7-73: Annual - Cadonilimab Sales (US$ Million), H2’2022 and H1’2023
Figure 8-1: Global - Multispecific Antibodies Clinical Trials by Phase (Numbers), 2024 till 2029
Figure 8-2: Global - Bispecific Antibodies Clinical Trials by Phase (Numbers), 2024 till 2029
Figure 8-3: Global - Tetraspecific Antibodies Clinical Trials By Phase (Number Of Antibodies), 2024 till 2029
Figure 8-4: Global - Trispecific Antibodies Clinical Trials by Phase, 2024 till 2029
Figure 8-5: Global - Bispecific Antibodies in Clinical Trials by Country (Numbers), 2024 till 2029
Figure 8-6: Global - Tetraspecific Antibodies Clinical Trials By Company (Number Of Trials), 2024 till 2029
Figure 8-7: Global - Trispecific Antibodies Clinical Trials by Country, 2024 till 2029
Figure 8-8: Global - Bispecific Antibodies in Clinical Trials by Company (Numbers), 2024 till 2029
Figure 8-9: Global - Tetraspecific Antibodies Clinical Trials By Company (Number Of Antibodies), 2024 till 2029
Figure 8-10: Global - Trispecific Antibodies Clinical Trials by Company, 2024 till 2029
Figure 8-11: Global - Bispecific Antibodies in Clinical Trials by Indication (Numbers), 2023 till 2029
Figure 8-12: Global - Tetraspecific Antibodies Clinical Trials By Indication (Number Of Trials), 2024 till 2029
Figure 8-13: Global - Trispecific Antibodies Clinical Trials by Indication, 2024 till 2029
Figure 8-14: Global - Bispecific Antibodies in Clinical Trials by Orphan Status (Numbers), 2024 till 2029
Figure 8-15: Global - Bispecific Antibodies in Clinical Trials by Patient Segment (Numbers), 2024 till 2029
Figure 8-16: Global - Trispecific Antibodies Clinical Trials by Patient Segment, 2024 till 2029
Table 2-1: Estimated Total Cancer Cases, 2022 and 2040
Table 2-2: Next Generation Multispecific Antibody Market - Recent Collaborations
Table 2-3: Next Generation Multispecific Antibody Market - Recent Acquisitions
Table 2-4: Next Generation Multispecific Antibody Market - Recent Regulatory
Designations
Table 4-1: US - Multispecific Antibodies in Clinical Trials
Table 4-2: Europe - Multispecific Antibodies in Clinical Trials
Table 4-3: China - Multispecific Antibodies in Clinical Trials
Table 4-4: UK - Multispecific Antibodies in Clinical Trials
Table 4-5: Japan - Ongoing Clinical Trials for Next Generation Multispecific Antibodies
Table 4-6: Australia - Ongoing Clinical Trials for Next Generation Multispecific Antibodies
Table 4-7: South Korea - Ongoing Clinical Trials for Next Generation Multispecific Antibodies
Table 4-8: Canada - Ongoing Clinical Trials for Next Generation Multispecific Antibodies
Table 5-1: Hematological Cancers - Approved Multispecific Antibodies
Table 5-2: Hematological Malignancies - Estimated Total Cancer Cases, 2022 and 2040
Table 5-3: Solid Cancers - Approved Multispecific Antibodies
Table 5-4: Solid Cancers - Estimated Total Cancer Cases, 2022 and 2040
Table 5-5: Vabysmo - Approval Year by Indication
Table 6-1: Approved Multispecific Antibodies
Table 6-2: Blincyto - Active Patents
Table 6-3: Blincyto - Recommended Dosage and Schedule for the Treatment of MRD-positive B-cell Precursor ALL
Table 6-4: Blincyto - Recommended Dosage and Schedule for Treatment of Relapsed or Refractory B-cell Precursor ALL
Table 6-5: Blincyto - Recommended Dosage and Schedule for Treatment of Relapsed or Refractory B-cell Precursor ALL
Table 6-6: Rybrevant - Premedication
Table 6-7: Rybrevant - Dose Reductions for Adverse Reactions
Table 6-8: Rybrevant - Recommended Dosage Modifications for Adverse Reactions
Table 6-9: Lunsumio - Recommended Treatment Cycles
Table 6-10: Lunsumio - Recommended Premedications
Table 6-11: Lunsumio - Recommendations for Management of Cytokine Release Syndrome
Table 6-12: Tecvayli - Dosing Schedule
Table 6-13: Tecvayli - Recommended Dosage Modifications for Adverse Reactions
Table 6-14: Columvi - Dosing Schedule (21-Day Treatment Cycles)
Table 6-15: Columvi - Premedications to be Administered
Table 6-16: Columvi - Recommendations for Management of Cytokine Release Syndrome
Table 6-17: Columvi - Recommended Dosage Modification for Neurologic Toxicity (Including ICANS)
Table 6-18: Columvi - Recommended Dosage Modifications for Other Adverse Reactions
Table 6-19: Epkinly - Dosage Schedule
Table 6-20: Epkinly - Recommendations for Management of Cytokine Release Syndrome
Table 6-21: Epkinly - Recommendations for Management of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
Table 6-22: Epkinly - Recommended Dosage Modifications for Other Adverse Reactions
Table 6-23: Talvey - Weekly Dosing Schedule
Table 6-24: Talvey - Biweekly Dosing Schedule
Table 6-25: Talvey - Recommendations for Management of CRS
Table 6-26: Talvey - Recommendations for Management of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
Table 6-27: Talvey - Recommendations for Management of Neurologic Toxicity (excluding ICANS)
Table 6-28: Talvey - Recommended Dosage Modifications for Other Adverse Reactions
Table 6-29: Elrexfio - Dosing Schedule
Table 6-30: Elrexfio - Recommendations for Management of CRS
Table 6-31: Elrexfio - Recommended Dosage Modifications for Other Adverse Reactions
Table 6-32: Imdelltra - Recommended Concomitant Medications for Administration for Cycle
Table 6-33: Imdelltra - Recommended Dosage and Schedule of
Table 6-34: Imdelltra - Recommendations for Restarting Therapy After Dosage Delay
Table 6-35: Imdelltra - Guidelines for Grading and Dosage Modification and Management of Cytokine Release Syndrome
Table 6-36: Imdelltra - Guidelines for Management of Neurologic Toxicity including Immune Effector Cell-Associated Neurotoxicity Syndrome